You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,718,193

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,718,193 protect, and when does it expire?

Patent 8,718,193 protects ABILIFY MYCITE KIT and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,718,193

Patent landscape, scope, and claims:

Title:	Active signal processing personal health signal receivers
Abstract:	The invention provides a receiver associated with a body, e.g., located inside or within close proximity to a body, configured to receive and decode a signal from an in vivo transmitter which located inside the body. Signal receivers of the invention provide for accurate signal decoding of a low-level signal, even in the presence of significant noise, using a small-scale chip, e.g., where the chip consumes very low power. Also provided are systems that include the receivers, as well as methods of using the same.
Inventor(s):	Arne; Lawrence (Redwood City, CA), Au-Yeung; KitYee (San Francisco, CA), Crandall; Kenneth C. (Sunnyvale, CA), Robertson; Timothy (Belmont, CA)
Assignee:	Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:	12/515,527
Patent Claim Types: see list of patent claims	Composition;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,718,193

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-001	Nov 13, 2017		RX	Yes	No	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		RX	Yes	Yes	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		RX	Yes	No	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017		RX	Yes	No	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017		RX	Yes	No	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017		RX	Yes	No	8,718,193	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,718,193

PCT Information
PCT Filed	November 19, 2007	PCT Application Number:	PCT/US2007/024225
PCT Publication Date:	May 29, 2008	PCT Publication Number:	WO2008/063626

International Family Members for US Patent 8,718,193

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2069004	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2008063626	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.